abstract |
The use of an S1P receptor modulator of the formula (Ia) or (Ib) wherein the meaning of the different residues is that indicated in claim 14 , in the preparation of a medicament for preventing, inhibiting or treating an inflammatory condition selected from polymyositis, dermatomyositis and nerve-muscle diseases e.g. muscular dystrophies and inclusion body myositis. |